Elevated NCOR1 disrupts PPARα/γ signaling in prostate cancer and forms a targetable epigenetic lesion-Reference-Cited by-同舟云学术

Elevated NCOR1 disrupts PPARα/γ signaling in prostate cancer and forms a targetable epigenetic lesion

Published:2010-05-13 Issue:9 Volume:31 Page:1650-1660
ISSN:1460-2180
Container-title:Carcinogenesis
language:en
Short-container-title:

Author:

Battaglia Sebastiano,Maguire Orla,Thorne James L.,Hornung Laura B.,Doig Craig L.,Liu Song,Sucheston Lara E.,Bianchi Anna,Khanim Farhat L.,Gommersall Lyndon M.,Coulter Henry S.O.,Rakha Serena,Giddings Ian,O'Neill Laura P.,Cooper Colin S.,McCabe Christopher J.,Bunce Christopher M.,Campbell Moray J.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,General Medicine

Link

http://academic.oup.com/carcin/article-pdf/31/9/1650/17288991/bgq086.pdf

Reference63 articles.

1. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response;Rosenfeld;Genes Dev.,2006

2. Deconstructing repression: evolving models of co-repressor action;Perissi;Nat. Rev. Genet.,2010

3. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron;Jepsen;Nature,2007

4. The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo;Astapova;Proc. Natl Acad. Sci. USA,2008

5. SMRT repression of nuclear receptors controls the adipogenic set point and metabolic homeostasis;Nofsinger;Proc. Natl Acad. Sci. USA,2008

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growth;Translational Oncology;2024-09

2. Effects of conceptus proteins on endometrium and blood leukocytes of dairy cattle using transcriptome and meta-analysis;2024-04-28

3. Vitamin D and prostate cancer;Feldman and Pike's Vitamin D;2024

4. Epigenetic disruption of the RARγ complex impairs its function to bookmark AR enhancer interactions required for enzalutamide sensitivity in prostate cancer;2023-12-16

5. The MYC axis in advanced prostate cancer is impacted through concurrent targeting of ERβ and AR using a novel ERβ-selective ligand alongside Enzalutamide;2023-11-17